Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.32 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23942638 | 0.85 | SORT1 (0.33) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL24928215 | 0.84 | CYP1A2 (0.35) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL14867639 | 0.83 | CYP2C19 (0.38) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL13336153 | 0.81 | NOS3 (0.31) | POLBKMT2A | |
| SCHEMBL18118981 | 0.78 | ALDH1A1 (0.39) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL20457091 | 0.76 | TP53 (0.32) | CYP2C19CYP2C9SMN1; SMN2HIF1ATP53 | |
| SCHEMBL20457084 | 0.76 | SMN1; SMN2 (0.35) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL25873927 | 0.72 | — | — | |
| SCHEMBL14019766 | 0.70 | NUDT1 (0.36) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL21500716 | 0.68 | CYP2C9 (0.46) | CYP2C19CYP1A2CYP2C9SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210040099-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210032263-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | CYP2C19 4454/4885CYP1A2 3994/4885CYP2C9 4739/4885 |
| US-20210040099-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | CYP2C19 4454/4885CYP1A2 3994/4885CYP2C9 4739/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | CYP2C19 4454/4885CYP1A2 3994/4885CYP2C9 4739/4885 |
| US-20210032263-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | CYP2C19 4467/4885CYP1A2 4023/4885CYP2C9 4744/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | CYP2C19 4467/4885CYP1A2 4023/4885CYP2C9 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.